Hypogammaglobulinemia is a poorly described complication of chemotherapy in adolescents and young adults (AYAs, 15–39 years) with acute lymphoblastic leukemia (ALL). The majority of AYAs treated on a Berlin–Frankfurt–Munster-based ALL regimen experienced hypogammaglobulinemia (65.0% [13/20]). Febrile neutropenia episodes (throughout the treatment course) and infectious events during maintenance occurred more frequently in hypogammaglobulinemic patients compared with patients with normal immunoglobulin G levels (n = 7) (median 1.0 vs. 0.0, p = 0.02; 7.0 vs. 3.0, p = 0.02, respectively). Hypogammaglobulinemia did not impact overall or event-free survival. Further studies are needed to elucidate the etiology of hypogammaglobulinemia and to establish criteria for immunoglobulin replacement in these patients.
Get full access to this article
View all access options for this article.
References
1.
HowladerN, NooneAM, KrapchoM, et al. SEER cancer statistics review, 1975–2016. Bethesda, MD: National Cancer Institute; April 2019. Table 32.1, Age-adjusted SEER incidence, by age group and sex, by adapted classification scheme for tumors of adolescents and young adults, all races, 2012–2016. Accessed June27, 2019 from: https://seer.cancer.gov/csr/1975_2016/results_single/sect_32_table. 01_2pgs.pdf
2.
StockW, LugerSM, AdvaniAS, et al.A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 133(14):1548–59.
3.
PuiCH, PeiD, CampanaD, et al.Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011; 29:386–91.
PerkinsJL, HarrisA, PozosTC. Immune dysfunction after completion of childhood leukemia therapy. J Pediatr Hematol Oncol. 2017; 39(1):1–5.
6.
KostaridouS, PolychronopoulouS, PsarraK, et al.Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance. Int J Hematol. 2004; 80(4):354–60.
7.
Martín IbáñezI, Arce CasasA, Cruz MartínezO, et al.Humoral immunity in pediatric patients with acute lymphoblastic leukaemia. Allergol Immunopathol (Madr). 2003; 31(6):303–10.
8.
LuczynskiW, Stasiak-BarmutaA, Krawczuk-RybakM. Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children-preliminary report. Pediatr Blood Cancer. 2004; 42(5):416–20.
9.
El-ChennawiFA, Al-TonbaryYA, MossadYM, AhmedMA. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection. Hematology. 2008; 13(4):203–9.
10.
KosmidisS, BakaM, BouhoutsouD, et al.Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer. 2008; 50(3):528–32.
11.
De AngelisF, TostiME, CapriaS, et al.Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res. 2015; 39(12):1382–8.
12.
BrusamolinoE, RusconiC, MontalbettiL, et al.Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large Bcell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006; 91(4):496–502.
13.
JolliffCR, CostKM, StivrinsPC, et al.Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem. 1982; 28(1):126–8.
14.
NicholsonJF, PesceMA. Table 726–6, Reference Ranges. In: Behrman RE, Kliegman RM, Jenson HB, (Eds). Nelson textbook of pediatric. 16th ed. Philadelphia: W.B. Saunders Company; 2001. p.2202.
15.
AgarwalS, Cunningham-RundlesC. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007; 99(3):281–3.
16.
HolmesEA, FriedmanDL, ConnellyJA, et al.Impact of IgG monitoring and IVIG supplementation on the frequency of febrile illnesses in pediatric acute lymphoblastic leukemia patients undergoing maintenance chemotherapy. J Pediatr Hematol Oncol. 2019; 41(6):423–8.
17.
SteinherzPG, SeibelNL, SatherH, et al.Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group. Leukemia. 2019; 33(9):2144–54.
18.
VroomanLM, BlonquistTM, HarrisMH, et al.Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05–001. Blood Adv. 2018; 2(12):1449–58.
19.
TerwilligerT, Abdul-HayM. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J [Internet]. 2017; 7(6):e577.
20.
RiveraGK, HudsonMM, LiuQ, et al.Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood. 1996; 88(3):831–7.
21.
KatsimpardiK, PapadakisV, PangalisA, et al.Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer. 2006; 14(3):277–84.
22.
GimesiA, EiblM, KoósR, et al.Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children. Acta Paediatr Hung. 1992; 32(2):115–25.
23.
Van WinkleP, BurchetteR, KimR, et al.Prevalence and safety of intravenous immunoglobulin administration during maintenance chemotherapy in children with acute lymphoblastic leukemia in first complete remission: a health maintenance organization perspective. Perm J. 2018; 22:17–141.
24.
BarmettlerS, OngMS, FarmerJR, et al.Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open [Internet]. 2018; 1(7):e184169.
25.
VillanuevaG, de JongJLO, McNeerJL. Intravenous immunoglobulin in the treatment of hematologic disorders in pediatrics. Pediatr Ann [Internet]. 2017; 46(1):e13–e18.
